Takeda, Zinfandel link may revive ACTOS in Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Takeda became the latest of the major pharmaceutical companies to turn to biomarker-based diagnostics its approach to Alzheimer’s disease when it signed an exclusive, worldwide licensing agreement with Zinfandel Pharmaceuticals on the development of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease. However, recently published research elsewhere suggests that a full understanding of the biology of the disease may not be necessary in identifying potential Alzheimer's diagnostics.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.